Bolt Biotherapeutics Q2 2023 cash $157.1M, initiates BDC-1001 Phase 2, gets IND for BDC-3042

Bolt Biotherapeutics, Inc.

2023-Q2 EPS reported -$0.93 revenue$3,259,000

Cash, equivalents and marketable securities $157.1M as of June 30, 2023; runway expected through 2025.
First patients dosed in BDC-1001 Phase 2 dose-expansion study for HER2+ colorectal, endometrial, and gastroesophageal cancers.
FDA cleared IND for BDC-3042 (Dectin-2 agonist) in July 2023; Phase 1 start expected later in 2023.
Loss from operations $19.8M in Q2 2023 vs $23.1M in Q2 2022; R&D expenses reduced to $15.6M from $18.9M.
Collaboration revenue flat at $1.4M; G&A essentially unchanged at $5.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.